Miragen Therapeutics Inc (NASDAQ:MGEN) Receives $20.50 Average PT from Brokerages

Miragen Therapeutics Inc (NASDAQ:MGEN) has been given a consensus rating of “Buy” by the six research firms that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $20.50.

Several analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Miragen Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 11th. Wedbush reissued a “buy” rating and issued a $24.00 price target on shares of Miragen Therapeutics in a research note on Tuesday, May 21st. Finally, ValuEngine raised shares of Miragen Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st.

Several large investors have recently bought and sold shares of the company. BlackRock Inc. grew its holdings in shares of Miragen Therapeutics by 3.4% during the fourth quarter. BlackRock Inc. now owns 1,459,881 shares of the medical research company’s stock valued at $4,423,000 after buying an additional 48,128 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Miragen Therapeutics by 5.3% during the fourth quarter. Geode Capital Management LLC now owns 230,127 shares of the medical research company’s stock valued at $697,000 after buying an additional 11,541 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Miragen Therapeutics by 2.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 216,866 shares of the medical research company’s stock valued at $657,000 after buying an additional 4,404 shares during the last quarter. Deutsche Bank AG grew its holdings in shares of Miragen Therapeutics by 266.7% during the fourth quarter. Deutsche Bank AG now owns 190,653 shares of the medical research company’s stock valued at $577,000 after buying an additional 138,657 shares during the last quarter. Finally, Motley Fool Asset Management LLC grew its holdings in shares of Miragen Therapeutics by 19.8% during the first quarter. Motley Fool Asset Management LLC now owns 173,998 shares of the medical research company’s stock valued at $485,000 after buying an additional 28,760 shares during the last quarter. Hedge funds and other institutional investors own 42.81% of the company’s stock.

Miragen Therapeutics stock opened at $1.87 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 7.90 and a quick ratio of 7.90. The company has a market capitalization of $57.84 million, a P/E ratio of -1.70 and a beta of 1.12. The stock has a fifty day simple moving average of $2.18. Miragen Therapeutics has a twelve month low of $1.84 and a twelve month high of $6.62.

Miragen Therapeutics (NASDAQ:MGEN) last posted its quarterly earnings results on Wednesday, May 8th. The medical research company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.03). The business had revenue of $0.37 million during the quarter, compared to the consensus estimate of $1.35 million. Miragen Therapeutics had a negative return on equity of 71.91% and a negative net margin of 998.26%. As a group, analysts predict that Miragen Therapeutics will post -1.41 earnings per share for the current year.

About Miragen Therapeutics

Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan.

Featured Article: The Structure of a Futures Contract

Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.